FOG-001 in Locally Advanced or Metastatic Solid Tumors
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
What the trial team says
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Key facts
- Registry number
- NCT05919264
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, WNT Pathway, HCC, Desmoid, Microsatellite Stable Colorectal Cancer, Metastatic Castration-resistant Prostate Cancer, Familial Adenomatous Polyposis (FAP), Endometrial Carcinoma, Prostate Cancer, Microsatellite Instability-High Colorectal Cancer, Adamantinomatous Craniopharyngioma
Where it is running
This trial lists 33 sites.
-
Arizona
- Mayo Clinic (Phoenix)
- Honor Health (Scottsdale)
- Arizona Cancer Center at University of Arizona (Tucson)
-
California
- University of California, Los Angeles (UCLA) (Los Angeles)
- Stanford Cancer Institute, Stanford University (Palo Alto)
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center (San Francisco)
- Sarcoma Oncology Center (Santa Monica)
-
Colorado
- University of Colorado (Aurora)
-
Connecticut
- Yale University School of Medicine (New Haven)
-
District of Columbia
- Johns Hopkins University, Sibley Memorial Hospital (Washington D.C.)
-
Florida
- Mayo Clinic (Jacksonville)
- Florida Cancer Specialists (Lake Mary)
-
Maryland
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center (Baltimore)
-
Massachusetts
- Massachusetts General Hospital (Boston)
- Dana Farber Cancer Institute (Boston)
-
Minnesota
- M Health Fairview University of Minnesota Medical Center (Minneapolis)
- Mayo Clinic (Rochester)
-
Missouri
- Washington University School of Medicine (St Louis)
-
New York
- Memorial Sloan Kettering Cancer Center (New York)
-
North Carolina
- Duke University (Durham)
-
Ohio
- University Hospitals Cleveland Medical Center, Seidman Cancer Center (Cleveland)
- Cleveland Clinic (Cleveland)
-
Oregon
- Oregon Health and Science University (Portland)
-
Pennsylvania
- University of Pennsylvania, Perelman School of Medicine (Philadelphia)
- University of Pittsburgh Medical Center, Hillman Cancer Center (Pittsburgh)
-
Queensland
- Integrated Clinical Oncology Network (ICON) (South Brisbane)
-
Tennessee
- Sarah Cannon Research Institute (Nashville)
- Vanderbilt Ingram Cancer Center (Nashville)
-
Texas
- The University of Texas MD Anderson Cancer Center (Houston)
- South Texas Accelerated Research Therapeutics, LLC (San Antonio)
-
Victoria
- Peter MacCallum Cancer Centre (Melbourne)
-
Virginia
- University of Virginia (Charlottesville)
-
Wisconsin
- University of Wisconsin, Carbone Cancer Center (Madison)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.